• Home>
  • Stocks>
  • Astrazeneca Pharma India Ltd Share Price
Astrazeneca Pharma India Ltd share price logo

Astrazeneca Pharma India Ltd Share Price

(ASTRAZEN)

₹8607.651.33%

as on 04:01PM, 28 Mar 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Astrazeneca Pharma India Ltd Performance

  • Day's Low

    Day's High

    ₹8,430.3
    Day's Price Range
    ₹8,759
  • 52 Week's Low

    52 Week's High

    ₹4,800.15
    52-Week Price Range
    ₹9,059.05
1 Month Return+ 25.51 %
3 Month Return+ 19.62 %
1 Year Return+ 65.51 %
Previous Close₹8,494.65
Open₹8,510.00
Volume30.40K
Upper Circuit₹10,193.55
Lower Circuit₹6,795.75
Market Cap₹21,519.13Cr

Astrazeneca Pharma India Ltd Fundamentals

P/E Ratio

0

PEG Ratio

0

Market Cap

₹21,519.13 Cr

P/B Ratio

18.68

EPS

0

Dividend Yield

0

Sector

Pharmaceuticals

ROE

24.84

Key events for Astrazeneca Pharma India Ltd

  • AstraZeneca to Discontinue Imdur Production - 28 Mar, 2025

    AstraZeneca Pharma India Limited will cease the manufacturing and marketing of Imdur (Isosorbide-5-mononitrate Tablets) effective April 1, 2025, impacting patients and healthcare providers.
  • AstraZeneca Faces Tax Challenge Amid Strong Stock Momentum - 19 Mar, 2025

    AstraZeneca Pharma India is experiencing strong stock momentum, trading near its lifetime high. However, it faces a draft order from the Income Tax Department regarding transfer pricing issues, which the company plans to contest.
  • Trading Recommendation for Astrazeneca Pharma - 12 Mar, 2025

    Traders are advised to buy Astrazeneca Pharma shares in the range of ₹7750–₹7850, with a stop-loss at ₹7500 and a target of ₹8400 over the next 1–3 months.
  • AstraZeneca Pharma India Reports Strong Growth - 11 Mar, 2025

    AstraZeneca Pharma India, promoted by AstraZeneca Plc, has shown robust performance with a 40% return over the past year, 20% CAGR in net profit over three years, and a debt-free status. In Q3FY25, the company reported a 43% YoY sales growth and a remarkable 95% increase in net profit.
  • AstraZeneca Gains Approval for Lung Cancer Drug - 07 Mar, 2025

    AstraZeneca Pharma India Limited has received approval from CDSCO to import and sell Durvalumab (Imfinzi) for treating limited-stage small cell lung cancer, enhancing treatment options for patients.
  • AstraZeneca Gains Approval for New Hyperkalaemia Drug - 06 Mar, 2025

    AstraZeneca Pharma India Ltd has received approval from the CDSCO to import sodium zirconium cyclosilicate powder (Lokelma) for treating hyperkalaemia in adults, expanding treatment options in India.
  • AstraZeneca Shares Surge Amid Positive Momentum - 05 Mar, 2025

    AstraZeneca Pharma India Ltd shares rose 6.5% to ₹7,306, reflecting a 34% annual gain, despite a recent correction from record highs.
  • AstraZeneca Pharma Secures CDSCO Approval for Cancer Drug - 03 Mar, 2025

    AstraZeneca Pharma India Ltd received CDSCO approval to import and distribute Durvalumab for treating unresectable hepatocellular carcinoma, boosting its oncology portfolio.

Insights on Astrazeneca Pharma India Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 2.90% to 2.93% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ASTRAZEN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, ASTRAZEN stock has moved up by 25.5%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ASTRAZEN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 75.00% of holdings in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 5.05% to 5.04% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 17.00% to 16.85% in Dec 2024 quarter

Astrazeneca Pharma India Ltd Financials

Value in ₹ crore
Details2021202220232024
Total Assets₹777.49Cr (-)₹858.43Cr (↑10.41%)₹986.40Cr (↑14.91%)₹1,079.09Cr (↑9.40%)
Total Liabilities₹321.32Cr (-)₹347.04Cr (↑8.00%)₹397.71Cr (↑14.60%)₹367.17Cr (↓7.68%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹87.42Cr (-)₹104.78Cr (↑19.86%)₹100.80Cr (↓3.80%)₹58.29Cr (↓42.17%)₹27.87Cr (↓52.19%)

Astrazeneca Pharma India Ltd Index Inclusions

BSE Healthcare

₹41,421.50

-0.12 (-48.19%)

Nifty Smallcap 250

₹15,104.05

-0.05 (-7.6%)

Nifty 500

₹21,339.55

-0.32 (-68.4%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Nifty MidSmallcap 400

₹17,677.95

-0.2 (-36.15%)

S&P BSE 250 SmallCap

₹6,039.25

-0.45 (-27.45%)

BSE 500

₹33,579.22

-0.39 (-132.39%)

S&P BSE 400 MidSmallCap

₹10,772.07

-0.52 (-56.71%)

BSE Small-Cap

₹46,638.13

-0.35 (-165.52%)

Astrazeneca Pharma India Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
75%
0.00
Foreign Institutions
2.93%
1.02
Mutual Funds
5.04%
-0.14
Retail Investors
16.85%
-0.88
Others
0.18%
270.61

Astrazeneca Pharma India Ltd Key Indicators

Details20202021202220232024
Return On Equity %21.7122.7412.7322.9524.84

Astrazeneca Pharma India Ltd Earnings and Dividends

  • Astrazeneca Pharma India Ltd Earnings Results

    Astrazeneca Pharma India Ltd’s net profit jumped 95.25% since last year same period to ₹30.85Cr in the Q3 2024-2025. On a quarterly growth basis, Astrazeneca Pharma India Ltd has generated -19.72% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Astrazeneca Pharma India Ltd Dividends May,2024

    In the quarter ending March 2024, Astrazeneca Pharma India Ltd has declared dividend of ₹24 - translating a dividend yield of 0.46%.

    Read More about Dividends

Astrazeneca Pharma India Ltd Technicals Summary

Bearish

Neutral

Bullish

Bullish

Astrazeneca Pharma India Ltd is currently in a Bullish trading position according to technical analysis indicators.

Astrazeneca Pharma India Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
NA₹21,519.13 Cr51.46%0.51NANA
BUY₹29,300.43 Cr193.09%0.52₹300 Cr₹1,051 Cr
BUY₹14,271.69 Cr57.79%0.57₹72 Cr₹6,702 Cr
NA₹4,800.00 Cr10.26%0.79-₹388 Cr₹75 Cr
BUY₹14,234.50 Cr42.27%0.68₹218 Cr₹1,296 Cr

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on the 11th of July 1979 and is a subsidiary of AstraZeneca Pharmaceuticals AB Sweden, which is an indirect subsidiary of AstraZeneca Plc. It is engaged in manufacture, distribution and marketing of pharmaceutical products in therapy areas such as Onocology, Alimentary Metabolism, Cardio Vascular, Renal Diabetes, Respiratory and Oncology. The company suffered a performance setback due to supply stabilization in 2012, following which the current year witnessed series of regulatory interventions in the Indian Pharmaceutical Market covering 348 medicines including 15 SKUs across 8 brands of the company listed on the National List of Essential Medicines (NLEM). During the year, APIL introduced Arimidex, an Oncology product for the management of breast cancer and decided to make its Astrazeneca India’s RD as a part of its global RD organisation. In 2013-14, the market share of drug brand Brilinta (Ticagrelor) which provides cardiologists with a new and effective treatment to help reduce the rate of heart attack and cardiovascular deaths grew from 1.4 MAT March 2013 to 6.7 MAT March 2014. For the FY 2013-14, the company experienced a range of patient price reduction of 452 and an average price reduction of 30. In 2015-16, key growth brands of APIL such as Brilinta, Forxiga, Onglyza, Kombiglyze, Symbicort witnessed robust growth and diabetes portfolio grew by 74 post acquisition from Bristol MyersSquibb. Meanwhile, Meronem became the company’s first brand to cross the Rs. 100 crore sales milestone. The company entered into three Distribution Services Agreements with Dr. Reddy's Laboratories, Sun Pharma for Ticagrelor and Diabetes treatments, while APIL, Dr. Reddy's Laboratories and Sun Pharma copromote market and distributed Saxagliptin, Dapagliflozin and Ticagrelor under different brand names in Indian markets. During 2017-18, the company aligned its portfolio to AstraZeneca's Global therapeutic focus and introduced Xigduo, a fixed dose combination drug to improve glycemic control for type 2 diabetes mellitus. In 2020-21, the company launched Lynparza, Calquence Acalabrutinib and Benralizumab

Listing date: 30 Jul, 1998
Chairperson Name: Narayan K Seshadri
OrganisationAstrazeneca Pharma India Ltd
HeadquartersBangalore
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Astrazeneca Pharma India Ltd

What is Astrazeneca Pharma India Ltd price today?

Astrazeneca Pharma India Ltd share price today stands at ₹8607.65, Open: ₹8510, Previous Close: ₹8494.65, High: ₹8759, Low: ₹8430.3, 52 Week High: ₹9059.05, 52 Week Low: ₹4800.15.

How to Buy Astrazeneca Pharma India Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Astrazeneca Pharma India Ltd shares

What are today's traded volumes of Astrazeneca Pharma India Ltd?

Today's traded volume of Astrazeneca Pharma India Ltd(ASTRAZEN) is 30.40K.

What is today's market capitalisation of Astrazeneca Pharma India Ltd?

Today's market capitalisation of Astrazeneca Pharma India Ltd(ASTRAZEN) is ₹21519.13Cr.

What is the 52 Week High and Low Range of Astrazeneca Pharma India Ltd?

Astrazeneca Pharma India Ltd (ASTRAZEN)
Price
52 Week High
₹9059.05
52 Week Low
₹4800.15

How much percentage Astrazeneca Pharma India Ltd is down from its 52 Week High?

Astrazeneca Pharma India Ltd (ASTRAZEN) share price is ₹8607.65. It is down -4.98% from its 52 Week High price of ₹9059.05

How much percentage Astrazeneca Pharma India Ltd is up from its 52 Week low?

Astrazeneca Pharma India Ltd (ASTRAZEN) share price is ₹8607.65. It is up 79.32% from its 52 Week Low price of ₹4800.15